Trials / Recruiting
RecruitingNCT07073534
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 203 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1501, Adebrelimab | the combination of SHR-1501 and Adebrelimab |
Timeline
- Start date
- 2025-07-24
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-07-18
- Last updated
- 2026-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07073534. Inclusion in this directory is not an endorsement.